Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade

被引:27
|
作者
Djuric-Stefanovic, A. [1 ,2 ]
Micev, M. [1 ,3 ]
Stojanovic-Rundic, S. [1 ,4 ]
Pesko, P. [1 ,5 ]
Saranovic, Dj [1 ,2 ]
机构
[1] Univ Belgrade, Fac Med, Belgrade 11001, Serbia
[2] Clin Ctr Serbia, Ctr Radiol & MR, Surg Univ Clin 1, Dept Digest Radiol, Belgrade, Serbia
[3] Clin Ctr Serbia, Surg Univ Clin 1, Dept Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Dept Radiat Oncol, Clin Radiat Oncol & Diagnost, Belgrade, Serbia
[5] Clin Ctr Serbia, Surg Univ Clin 1, Belgrade, Serbia
关键词
CT perfusion; Esophageal carcinoma; Neoadjuvant chemoradiotherapy; Response evaluation; Tumor regression grade; COMPUTED-TOMOGRAPHY; CANCER; THERAPY; PET; MANAGEMENT; SURVIVAL; UTILITY;
D O I
10.1016/j.ejrad.2015.09.025
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To analyze value of the computed tomography (CT) perfusion imaging in response evaluation of the esophageal carcinoma to neoadjuvant chemoradiotherapy (nCRT) using the histopathology as reference standard. Methods: Forty patients with the squamous cell esophageal carcinoma were re-evaluated after the nCRT by CT examination, which included low-dose CT perfusion study that was analyzed using the deconvolution-based CT perfusion software (Perfusion 3.0, GE). Histopathologic assessment of tumor regression grade (TRG) according to Mandard's criteria served as reference standard of response evaluation. Statistical analysis was performed using Spearman's rank correlation coefficient (rs) and Kruskal-Wallis's test. Results: The perfusion CT parameter values, measured after the nCRT in the segment of the esophagus that had been affected by neoplasm prior to therapy, significantly correlated with the TRG: blood flow (BF) (rs = 0.851; p <0.001), blood volume (BV) (rs = 0.732; p <0.001) and mean transit time (MU) (rs = 0.386; p = 0.014). Median values of BF and BV significantly differed among TRG 1-4 groups (p < 0.001), while maximal esophageal wall thickness did not (p = 0.102). Median BF and BV were gradually rose and MU decreased as TRG increased, from 21.4 ml/min/100 g (BF), 1.6 ml/100 g (BV) and 8.6s (MU) in TRG 1 group, to 37.3 ml/min/100 g, 3.5 ml/100 g and 7.5 s in TRG 2 group, 81.4 ml/min/100 g, 4.1 ml/100 g and 3.8 s in TRG 3 group, and 121.1 ml/min/100 g, 4.9 ml/100 g and 3.7 s in TRG 4 group. In all 15 patients who achieved complete histopathologic regression (TRG 1), BF was <30.0 ml/min/100 g. Conclusions: CT perfusion could improve the accuracy in response evaluation of the esophageal carcinoma to nCRT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:2477 / 2484
页数:8
相关论文
共 50 条
  • [11] Surgery is crucial for advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
    Chen, Haiquan
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06): : 2722 - 2723
  • [12] Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
    Hsu, Po-Kuei
    Yeh, Yi-Chen
    Chien, Ling-, I
    Huang, Chien-Sheng
    Hsu, Han-Shui
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 2048 - 2058
  • [13] Clinicopathological Significance of Pathologic Complete Lymph Node Regression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
    Po-Kuei Hsu
    Yi-Chen Yeh
    Ling-I Chien
    Chien-Sheng Huang
    Han-Shui Hsu
    Annals of Surgical Oncology, 2021, 28 : 2048 - 2058
  • [14] Role of 18F-FDG-PET/CT in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
    Sasaki, Ken
    Uchikado, Yasuto
    Okumura, Hiroshi
    Omoto, Itaru
    Kita, Yoshiaki
    Arigami, Takaaki
    Uenosono, Yoshikazu
    Owaki, Tetsuhiro
    Maemura, Kosei
    Natsugoe, Shoji
    ANTICANCER RESEARCH, 2017, 37 (02) : 859 - 864
  • [15] Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
    Guo, Xufeng
    Chen, Chunji
    Zhao, Jinbo
    Wang, Changchun
    Mei, Xinyu
    Shen, Jianfei
    Lv, Huilai
    Han, Yongtao
    Wang, Qifeng
    Lv, Jiahua
    Chen, Hainan
    Yan, Xiaolong
    Liu, Zhichao
    Zhang, Zhengyang
    Zhong, Qihong
    Jiang, Youhua
    Xu, Liwei
    Li, Xiaoyang
    Qian, Dong
    Ma, Dehua
    Ye, Minhua
    Wang, Chunguo
    Wang, Zimin
    Lin, Jiangbo
    Tian, Ziqiang
    Leng, Xuefeng
    Li, Zhigang
    JAMA SURGERY, 2025,
  • [16] Commentary: The Hydra: Residual esophageal squamous cell tumor after neoadjuvant chemoradiotherapy Comment
    Lin, Jules
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (06): : 1643 - 1644
  • [17] Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy
    Chao, Yin-Kai
    Chang, Chun-Bi
    Chuang, Wen-Yu
    Wen, Yu-Wen
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Yeh, Chi-Ju
    Liu, Yun-Hen
    MEDICINE, 2015, 94 (34) : e1407
  • [18] A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy
    Yu, Yongkui
    Wang, Wei
    Qin, Zimin
    Li, Haomiao
    Liu, Qi
    Ma, Haibo
    Sun, Haibo
    Bauer, Thomas L.
    Pimiento, Jose M.
    Gabriel, Emmanuel
    Birdas, Thomas
    Li, Yin
    Xing, Wenqun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [19] Patients with Upper Third of Esophageal Squamous Cell Carcinoma Have Better Tumor Regression After Neoadjuvant Immunochemotherapy
    He, Yan
    Yu, Jun
    Bao, Tao
    He, Xian-Dong
    Xie, Xian-Feng
    Chen, Xu
    Pu, Xiang-Shu
    Li, Kun-kun
    Li, Chang-Feng
    Xu, Ming-Fang
    Pu, Yu
    Jiang, Yu-Zhu
    Wang, Ying-Jian
    Guo, Wei
    ANNALS OF SURGICAL ONCOLOGY, 2025,
  • [20] Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
    Kawai, Takaharu
    Kochi, Mitsugu
    Fujii, Masashi
    Song, Keio
    Hagiwara, Ken
    Watanabe, Megumu
    Matsuno, Yoritaka
    Suda, Hiroshi
    Yagi, Renpei
    Takayama, Tadatoshi
    ANTICANCER RESEARCH, 2017, 37 (06) : 3301 - 3306